Genetics and biology of prostate cancer

• Published in: Genes & development Vol. 32; no. 17-18; pp. 1105 - 1140
• Main Authors: Wang, Guocan, Zhao, Di, Spring, Denise J., DePinho, Ronald A.
• Format: Journal Article
• Language: English
• Published: United States Cold Spring Harbor Laboratory Press 01.09.2018
• Subjects: Animals; Drug Resistance, Neoplasm; Gene Fusion; Humans; Male; Mice; Neoplasm Metastasis; Prognosis; Prostate - anatomy & histology; Prostatic Neoplasms - diagnosis; Prostatic Neoplasms - genetics; Prostatic Neoplasms - pathology; Prostatic Neoplasms - therapy; Review; Tumor Microenvironment; prostate cancer; tumor microenvironment; therapy resistance
• ISSN: 0890-9369; 1549-5477; 1549-5477
• DOI: 10.1101/gad.315739.118

Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer remains largely incurable even after intensive multimodal therapy. The lethality of advanced disease is driven by the lack of therapeutic regimens capable of generating durable responses in the setting of extreme tumor heterogeneity on the genetic and cell biological levels. Here, we review available prostate cancer model systems, the prostate cancer genome atlas, cellular and functional heterogeneity in the tumor microenvironment, tumor-intrinsic and tumor-extrinsic mechanisms underlying therapeutic resistance, and technological advances focused on disease detection and management. These advances, along with an improved understanding of the adaptive responses to conventional cancer therapies, anti-androgen therapy, and immunotherapy, are catalyzing development of more effective therapeutic strategies for advanced disease. In particular, knowledge of the heterotypic interactions between and coevolution of cancer and host cells in the tumor microenvironment has illuminated novel therapeutic combinations with a strong potential for more durable therapeutic responses and eventual cures for advanced disease. Improved disease management will also benefit from artificial intelligence-based expert decision support systems for proper standard of care, prognostic determinant biomarkers to minimize overtreatment of localized disease, and new standards of care accelerated by next-generation adaptive clinical trials.